{"id":"minodronate","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":{"chemblId":"CHEMBL319144","moleculeType":"Small molecule","molecularWeight":"322.15"},"aliases":["Difumi"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Geranylgeranyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, Farnesyl diphosphate synthase"},"_scrapedAt":"2026-03-27T23:55:19.062Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Osteoporosis","diseaseId":"osteoporosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05645289","phase":"PHASE4","title":"Efficacy and Safety of Minodronate in Patients With Low Back Pain","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2023-01-01","conditions":"Postmenopausal Osteoporosis","enrollment":72},{"nctId":"NCT05305183","phase":"PHASE3","title":"A Phase III Clinical Study of Minodronate Tablets in Postmenopausal Women With Osteoporosis","status":"UNKNOWN","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2022-05-31","conditions":"Osteoporosis","enrollment":330},{"nctId":"NCT02166437","phase":"","title":"Clinical Results of Bisphosphonate and Denosumab Therapy Following Teriparatide Therapy for Japanese","status":"UNKNOWN","sponsor":"Tomidahama Hospital","startDate":"2013-11","conditions":"Osteoporosis","enrollment":500},{"nctId":"NCT00212628","phase":"PHASE3","title":"Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2004-06","conditions":"Involutional Osteoporosis","enrollment":444}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"ATYPICAL FEMUR FRACTURE"},{"count":1,"reaction":"ABSCESS JAW"},{"count":1,"reaction":"ALVEOLAR OSTEITIS"},{"count":1,"reaction":"BONE DENSITY INCREASED"},{"count":1,"reaction":"BONE PAIN"},{"count":1,"reaction":"FALL"},{"count":1,"reaction":"FEMUR FRACTURE"},{"count":1,"reaction":"FRACTURE NONUNION"},{"count":1,"reaction":"GROIN PAIN"},{"count":1,"reaction":"OSTEITIS"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Bone"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Minodronate","genericName":"Minodronate","companyName":"Peking University Third Hospital","companyId":"peking-university-third-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}